SEARCH

SEARCH BY CITATION

References

  • 1
    Kaplan NM. Primary hypertension: pathogenesis. In: KaplanNM, ed. Clinical Hypertension. 8th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2002:56135.
  • 2
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP: the JNC 7 report. JAMA. 2003;289(19):25602572.
  • 3
    Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26(1):6069.
  • 4
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290(2):199206.
  • 5
    Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49(1):6975.
  • 6
    Smith NL, Chen L, Au DH, et al. Cardiovascular risk factor control among veterans with diabetes: the ambulatory care quality improvement project. Diabetes Care. 2004;27(suppl 2):B33B38.
  • 7
    Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):7679.
  • 8
    Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):112.
  • 9
    Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44(4):398404.
  • 10
    Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69e171.
  • 11
    Whyte JL, Lapuerta P, L'Italien GJ, et al. The challenge of controlling systolic BP: data from the National Health and Nutrition Examination Survey (NHANES III), 1988–1994. J Clin Hypertens (Greenwich). 2001;3(4):211216.
  • 12
    Colhoun HM, Dong W, Poulter NR. BP screening, management and control in England: results from the health survey for England 1994. J Hypertens. 1998;16(6):747752.
  • 13
    Sarafidis PA, Lasaridis A, Gousopoulos S, et al. Prevalence, awareness, treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa study. J Hum Hypertens. 2004;18(9):623629.
  • 14
    Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):1017.
  • 15
    Moser M, Franklin SS. Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich). 2007;9(5):316323.
  • 16
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):9951003.
  • 17
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):29812997.
  • 18
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):28052816.
  • 19
    Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early BP control rates: the ACCOMPLISH trial. Blood Press. 2007;16(2):8086.
  • 20
    Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007;77(1):126133.
  • 21
    Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98(2):204208.
  • 22
    Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(3):335342.
  • 23
    Parikh NI, Hwang SJ, Larson MG, et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006;166(17):18841891.
  • 24
    Chua DY, Bakris GL. Diabetes and chronic kidney disease: tragedy and challenge. Blood Purif. 2004;22(1):130135.
  • 25
    KEEP Annual Data Report. Am J Kidney Dis. 2007;49(3 suppl 2):1232.
  • 26
    Bakris GL, Weir MR. Achieving goal BP in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003;5(3):202209.
  • 27
    Kaplan NM. Resistant hypertension. J Hypertens. 2005;23(8):14411444.
  • 28
    Taler SJ. Treatment of resistant hypertension. Curr Hypertens Rep. 2005;7(5):323329.
  • 29
    Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med. 2006;355(4):385392.
  • 30
    Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002;4(3):221228.
  • 31
    Hall WD. Resistant hypertension, secondary hypertension, and hypertensive crises. Cardiol Clin. 2002;20(2):281289.
  • 32
    Oster JR, Materson BJ. Pseudohypertension: a diagnostic dilemma. J Clin Hypertens. 1986;2(4):307313.
  • 33
    Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14(12):12631269.
  • 34
    Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151(9):17861792.
  • 35
    Nilsson PM, Gudbjornsdottir S, Eliasson B, et al. Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. J Hum Hypertens. 2003;17(1):3744.
  • 36
    Wright JT Jr, Bakris G, Greene T, et al. Effect of BP lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):24212431.
  • 37
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):28052816.
  • 38
    Bakris GL, Weir MR, Shanifar S, et al. Effects of BP level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003;163(13):15551565.
  • 39
    Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005;46(6):13091315.
  • 40
    Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19(12):22712277.
  • 41
    Dickinson BD, Havas S. Reducing the population burden of cardiovascular disease by reducing sodium intake: a report of the Council on Science and Public Health. Arch Intern Med. 2007;167(14):14601468.
  • 42
    Hypertension in America: a national reading. Am J Manag Care. 2005;11(suppl 13):S383S385.
  • 43
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157(21):24132446.
  • 44
    Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: BP thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med. 2000;160(15):22812286.
  • 45
    Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162(4):413420.
  • 46
    Hajjar I, Miller K, Hirth V. Age-related bias in the management of hypertension: a national survey of physicians' opinions on hypertension in elderly adults. J Gerontol A Biol Sci Med Sci. 2002;57(8):M487M491.
  • 47
    Phillips CL, Cistulli PA. Obstructive sleep apnea and hypertension: epidemiology, mechanisms and treatment effects. Minerva Med. 2006;97(4):299312.
  • 48
    Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131(2):453459.
  • 49
    Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007;9(1 suppl 1):1924.
  • 50
    Douketis JD, Sharma AM. The management of hypertension in the overweight and obese patient: is weight reduction sufficient? Drugs. 2004;64(8):795803.
  • 51
    Ferdinand KC. Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with omapatrilat, a vasopeptidase inhibitor. J Clin Hypertens (Greenwich). 2001;3(5):307312.
  • 52
    Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest. 2006;36(suppl 3):7888.
  • 53
    Rubio ME, Banos G, Diaz E, et al. Effect of age on insulin-induced endothelin release and vasoreactivity in hypertriglyceridemic and hypertensive rats. Exp Gerontol. 2006;41(3):282288.
  • 54
    Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol. 2005;43(1):1929.
  • 55
    Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006;70(7):12231233.
  • 56
    Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14(suppl 5):S1S85.
  • 57
    Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). Drugs. 1999;58(suppl 1):710.
  • 58
    Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US Adults. Diabetes Care. 2004;27(10):24442449.
  • 59
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39(2 suppl 1):S1S266.
  • 60
    U.S. Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004.
  • 61
    Sonnenschein E, Brody JA. Effect of population aging on proportionate mortality from heart disease and cancer, U.S. 2000–2050. J Gerontol B Psychol Sci Soc Sci. 2005;60(2):S110S112.
  • 62
    Milchak JL, Carter BL, Ardery G, et al. Development of explicit criteria to measure adherence to hypertension guidelines. J Hum Hypertens. 2006;20(6):426433.